Rojo, F., Taylor, C. R., Barrios, C., & Torrecillas, L. (2025). FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.
Citación estilo ChicagoRojo, Federico, Clive R. Taylor, Carlos Barrios, y Laura Torrecillas. FOXC1 Expression Predicts Capecitabine Efficacy in Patients With Triple-Negative Breast Cancer From the GEICAM_CIBOMA Trial. 2025.
Cita MLARojo, Federico, Clive R. Taylor, Carlos Barrios, y Laura Torrecillas. FOXC1 Expression Predicts Capecitabine Efficacy in Patients With Triple-Negative Breast Cancer From the GEICAM_CIBOMA Trial. 2025.
Precaución: Estas citas no son 100% exactas.
